1. Home
  2. VTAK vs LABT Comparison

VTAK vs LABT Comparison

Compare VTAK & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catheter Precision Inc.

VTAK

Catheter Precision Inc.

HOLD

Current Price

$0.49

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$1.86

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTAK
LABT
Founded
2002
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
4.6M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
VTAK
LABT
Price
$0.49
$1.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.4M
253.1K
Earning Date
08-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
89.53
N/A
EPS
N/A
N/A
Revenue
$442,000.00
N/A
Revenue This Year
$1,170.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3057.14
N/A
52 Week Low
$0.15
$1.66
52 Week High
$4.31
$4.72

Technical Indicators

Market Signals
Indicator
VTAK
LABT
Relative Strength Index (RSI) 37.10 26.54
Support Level N/A $1.88
Resistance Level $1.22 $2.92
Average True Range (ATR) 0.17 0.43
MACD -0.05 -0.09
Stochastic Oscillator 12.86 12.50

Price Performance

Historical Comparison
VTAK
LABT

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: